LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

Search

Roivant Sciences Ltd

Closed

SectorHealthcare

27.33 -1.3

Overview

Share price change

24h

Current

Min

26.91

Max

27.92

Key metrics

By Trading Economics

Income

-200M

-314M

Sales

428K

2M

Profit margin

-15,692.896

Employees

750

EBITDA

-132M

-290M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+13.62% upside

Market Stats

By TradingEconomics

Market Cap

4.5B

20B

Previous open

28.63

Previous close

27.33

News Sentiment

By Acuity

50%

50%

149 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 lut 2026, 23:26 UTC

Major Market Movers

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 lut 2026, 22:31 UTC

Earnings

Correction to America Movil 4Q Profit Article

10 lut 2026, 22:22 UTC

Earnings

America Movil 4Q Profit Jumps on Lower Financial Costs

10 lut 2026, 23:51 UTC

Market Talk
Earnings

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 lut 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 lut 2026, 23:40 UTC

Market Talk
Earnings

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 lut 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 lut 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10 lut 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 lut 2026, 22:15 UTC

Earnings

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 lut 2026, 22:10 UTC

Earnings

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 lut 2026, 22:10 UTC

Earnings

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 lut 2026, 22:09 UTC

Earnings

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 lut 2026, 22:09 UTC

Earnings

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 lut 2026, 22:01 UTC

Earnings

Intact Financial 4Q EPS C$5.24 >IFC.T

10 lut 2026, 21:54 UTC

Earnings

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 lut 2026, 21:53 UTC

Earnings

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 lut 2026, 21:51 UTC

Earnings

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 lut 2026, 21:51 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 lut 2026, 21:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 lut 2026, 21:50 UTC

Earnings

James Hardie Industries 3Q EPS 12c >JHX

10 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 lut 2026, 21:50 UTC

Earnings

James Hardie Industries 3Q Adj EPS 24c >JHX

10 lut 2026, 21:49 UTC

Earnings

James Hardie Industries 3Q Sales $1.24B >JHX

10 lut 2026, 21:49 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 lut 2026, 21:48 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 lut 2026, 21:47 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

13.62% upside

12 Months Forecast

Average 31.44 USD  13.62%

High 38 USD

Low 26 USD

Based on 9 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

149 / 352 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat